SG11201909513QA - Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy - Google Patents
Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapyInfo
- Publication number
- SG11201909513QA SG11201909513QA SG11201909513QA SG11201909513QA SG 11201909513Q A SG11201909513Q A SG 11201909513QA SG 11201909513Q A SG11201909513Q A SG 11201909513QA SG 11201909513Q A SG11201909513Q A SG 11201909513QA
- Authority
- SG
- Singapore
- Prior art keywords
- pmpa
- international
- prodrugs
- psma
- radiotherapy
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 6
- 239000000651 prodrug Substances 0.000 title abstract 6
- 238000001959 radiotherapy Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000003384 imaging method Methods 0.000 title abstract 2
- ISEYJGQFXSTPMQ-UHFFFAOYSA-N 2-(phosphonomethyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(O)=O ISEYJGQFXSTPMQ-UHFFFAOYSA-N 0.000 abstract 8
- 210000003734 kidney Anatomy 0.000 abstract 3
- 210000001519 tissue Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000003079 salivary gland Anatomy 0.000 abstract 2
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 241001074037 Virginia Species 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 210000004561 lacrimal apparatus Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762484219P | 2017-04-11 | 2017-04-11 | |
| PCT/US2018/027106 WO2018191376A2 (en) | 2017-04-11 | 2018-04-11 | Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909513QA true SG11201909513QA (en) | 2019-11-28 |
Family
ID=63792979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909513Q SG11201909513QA (en) | 2017-04-11 | 2018-04-11 | Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy |
Country Status (11)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| AU2014336638C1 (en) | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US20160287731A1 (en) | 2013-11-14 | 2016-10-06 | Endocyte, Inc. | Compounds for Positron Emission Tomography |
| CA3097381A1 (en) | 2018-04-17 | 2019-10-24 | Endocyte, Inc. | Methods of treating cancer |
| JP7429688B2 (ja) * | 2018-09-21 | 2024-02-08 | エンドサイト・インコーポレイテッド | シールド剤およびそれらの使用 |
| WO2021202376A1 (en) * | 2020-03-30 | 2021-10-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs |
| CN115702009A (zh) * | 2020-04-29 | 2023-02-14 | 诺华股份有限公司 | 用于放射性标记psma结合配体的方法及其试剂盒 |
| IL297323A (en) * | 2020-04-29 | 2022-12-01 | Novartis Ag | Methods for radiological labeling of psma-binding ligands and their kits |
| CN113354709B (zh) * | 2021-06-03 | 2023-06-09 | 江苏华益科技有限公司 | 一种转移性前列腺癌靶向性药物前体的固相合成方法 |
| EP4536278A2 (en) | 2022-06-07 | 2025-04-16 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| WO2023239903A1 (en) * | 2022-06-09 | 2023-12-14 | Case Western Reserve University | Compositions and methods for preventing retention of psma-targeted therapy |
| US20250041461A1 (en) | 2023-07-31 | 2025-02-06 | Curium Us Llc | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof |
| WO2025167998A1 (zh) * | 2024-02-06 | 2025-08-14 | 北京昌平实验室 | 膦酸酯骨架的psma靶向偶联物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5951929B2 (ja) * | 2007-10-03 | 2016-07-13 | コーネル ユニヴァーシティー | Ｐｓｍａ抗体を用いる増殖性障害の治療 |
| CA2961575C (en) * | 2014-08-06 | 2023-09-19 | The Johns Hopkins University | Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors |
| RS63082B1 (sr) * | 2014-08-06 | 2022-04-29 | Univ Johns Hopkins | Lekovi inhibitora membranskog antigena specifičnog za prostatu (psma) |
| WO2016040179A1 (en) * | 2014-09-08 | 2016-03-17 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in psma-targeted radionuclide therapy of prostate cancer |
-
2018
- 2018-04-11 US US16/604,663 patent/US20200069706A1/en active Pending
- 2018-04-11 ES ES18783981T patent/ES3021195T3/es active Active
- 2018-04-11 KR KR1020197032774A patent/KR102686172B1/ko active Active
- 2018-04-11 EP EP18783981.6A patent/EP3609544B1/en active Active
- 2018-04-11 AU AU2018250609A patent/AU2018250609B2/en active Active
- 2018-04-11 SG SG11201909513Q patent/SG11201909513QA/en unknown
- 2018-04-11 CA CA3059741A patent/CA3059741A1/en active Pending
- 2018-04-11 CN CN201880034447.7A patent/CN111801121B/zh active Active
- 2018-04-11 JP JP2020506300A patent/JP2020530007A/ja active Pending
- 2018-04-11 WO PCT/US2018/027106 patent/WO2018191376A2/en active IP Right Grant
-
2019
- 2019-10-11 IL IL269969A patent/IL269969B2/en unknown
-
2023
- 2023-04-05 JP JP2023061616A patent/JP2023093545A/ja active Pending
-
2024
- 2024-11-14 JP JP2024199226A patent/JP2025028897A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200059187A (ko) | 2020-05-28 |
| EP3609544B1 (en) | 2025-04-09 |
| AU2018250609A1 (en) | 2019-10-31 |
| JP2020530007A (ja) | 2020-10-15 |
| CN111801121B (zh) | 2023-12-01 |
| ES3021195T3 (en) | 2025-05-26 |
| KR102686172B1 (ko) | 2024-07-17 |
| AU2018250609B2 (en) | 2024-05-09 |
| IL269969B2 (en) | 2023-04-01 |
| US20200069706A1 (en) | 2020-03-05 |
| JP2025028897A (ja) | 2025-03-05 |
| EP3609544A2 (en) | 2020-02-19 |
| CN111801121A (zh) | 2020-10-20 |
| EP3609544A4 (en) | 2020-12-23 |
| WO2018191376A3 (en) | 2018-12-27 |
| WO2018191376A2 (en) | 2018-10-18 |
| IL269969A (en) | 2022-12-01 |
| EP3609544C0 (en) | 2025-04-09 |
| JP2023093545A (ja) | 2023-07-04 |
| CA3059741A1 (en) | 2018-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909513QA (en) | Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy | |
| SG11201908790PA (en) | Glucocorticoid receptor modulators to treat cervical cancer | |
| SG11201809669RA (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11202000145XA (en) | Methods and systems for conditionally regulating gene expression | |
| SG11201900809TA (en) | Combination steerable catheter and systems | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201808003RA (en) | Bromodomain inhibitors | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201811237WA (en) | Combination therapies | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof |